, Columnist
Biotech Start-Ups Feel the Pain of Federal Funding Cuts
Government grants are critical to the research ecosystem, and patients will suffer.
The sign says it all.
Photographer: Scott Olson/Getty Images North AmericaThe Trump administration’s attack on the National Institutes of Health is strangling the biotech industry’s innovation engine — and it could get much worse.
The ongoing, brutal termination of grant funding for academic research has rightfully dominated the headlines. These cuts will eventually become a real problem, as fewer dollars mean fewer discoveries to be pulled from academia and into biotech and pharmaceutical companies.